Patents by Inventor Richard D. Olson

Richard D. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8158591
    Abstract: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: April 17, 2012
    Assignee: Gem Pharmaceuticals, LLC
    Inventors: Richard D. Olson, Gerald M. Walsh
  • Patent number: 8097707
    Abstract: 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthracyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthracyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: January 17, 2012
    Assignee: Gem Pharmaceuticals, LLC
    Inventors: Gerald M. Walsh, Richard D. Olson
  • Publication number: 20110028702
    Abstract: 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.
    Type: Application
    Filed: August 5, 2010
    Publication date: February 3, 2011
    Applicant: Gem Pharmaceuticals, LLC
    Inventors: Gerald M. Walsh, Richard D. Olson
  • Publication number: 20100311679
    Abstract: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.
    Type: Application
    Filed: August 17, 2010
    Publication date: December 9, 2010
    Applicant: Gem Pharmaceuticals, LLC
    Inventors: Richard D. Olson, Gerald M. Walsh
  • Patent number: 7776832
    Abstract: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: August 17, 2010
    Assignee: Gem Pharmaceuticals, LLC
    Inventors: Richard D. Olson, Gerald M. Walsh
  • Patent number: 7772379
    Abstract: 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 10, 2010
    Assignee: Gem Pharmaceuticals, LLC
    Inventors: Gerald M. Walsh, Richard D. Olson
  • Patent number: 7244829
    Abstract: 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: July 17, 2007
    Assignee: GEM Pharmaceuticals, LLC
    Inventors: Gerald M. Walsh, Richard D. Olson
  • Patent number: 5942605
    Abstract: 5-imino-13-deoxy anthracycline derivatives, medical uses of 5-imino-13-deoxy anthracycline derivatives and methods for preparing 5-imino-13-deoxy anthracycline derivatives.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: August 24, 1999
    Assignee: GEM Pharmaceuticals, Inc.
    Inventors: Xini Zhang, Richard D. Olson
  • Patent number: 4030058
    Abstract: The primary and secondary core sections of a split core transformer forming an inductive coupler are secured within separate sealed containments in intimate contact with a thin non-magnetic portion of the respective containments which permits inductive coupling and decoupling of the primary and secondary core sections in corrosive fluid environments such as water. The sealed containments isolate the core sections from contact with the corrosive environment thus permitting the use of efficient laminated iron in otherwise corrosive environments.
    Type: Grant
    Filed: March 30, 1976
    Date of Patent: June 14, 1977
    Assignee: Westinghouse Electric Corporation
    Inventors: Delmar R. Riffe, Richard D. Olson, David M. Edison, Robert J. Spreadbury